Unkei-to (TJ-106) induced significant increases of plasma
follicle stimulating hormone level in the first grade (P < 0.05), second grade
amenorrhea without
weight loss (P < 0.05), and
weight loss related to second grade
amenorrhea (P < 0.01) in eight weeks of treatment, respectively. Plasma
estradiol level significantly increased 1.8 times in 4 week treatment with
Unkei-to in first grade
amenorrhea (P < 0.01). In second grade
amenorrhea without
weight loss and
weight loss related second grade
amenorrhea, plasma
estradiol level significantly increased 2.9 times (P < 0.01) and 1.7 times (P < 0.05) in 8 weeks treatment, respectively. On the other hand, the patterns of pulsatile secretion of
follicle stimulating hormone and
luteinizing hormone remarkably improved by the treatment with
Unkei-to. In the patients with second grade
amenorrhea, follicles stimulating
hormone and
luteinizing hormone pulses appeared in 3 out of 13 (23.1%) and 6 out of 13 (46.2%) with the treatment of
Unkei-to, respectively in 85% of whom no pulses has been observed before the treatment. Ovulation occurred in 62.2% (23/37), 26.6% (4/15), and 21.7% (5/23) of the patients with first grade, second grade
amenorrhea without
weight loss, and
weight loss related second grade
amenorrhea by the treatment with
Unkei-to, respectively. These results indicate that
Unkei-to is effective on improvement of
gonadotropin pulsatile secretion in the treatment of anovulatory women. This suggests that
Unkei-to may enhance the pituitary response to
Gn-RH or improvement of the pulsatile secretion of
Gn-RH, inducing normalization of diencephalon-pituitary-ovarian endocrine system in the anovulatory patients.